Chronic obstructive pulmonary disease Trials in San Miguel de Tucumán, Argentina
Conditions / Chronic obstructive pulmonary disease / San Miguel de Tucumán, Argentina
Research into Chronic obstructive pulmonary disease spans multiple therapeutic approaches and trial phases.
18 total trials for this combination
Showing top 10 of 18 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04053634 | Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations | COMPLETED | PHASE3 |
| NCT01120691 | Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations | COMPLETED | PHASE3 |
| NCT04636814 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) | TERMINATED | PHASE3 |
| NCT07190209 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | RECRUITING | — |
| NCT03930732 | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation | COMPLETED | PHASE3 |
| NCT02760329 | Observational Study of Obstructive Lung Disease (NOVELTY) | COMPLETED | — |
| NCT07190209 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | RECRUITING | — |
| NCT04636801 | A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) | TERMINATED | PHASE3 |
| NCT05878769 | A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | RECRUITING | PHASE3 |
| NCT00845728 | Exacerbation Study | COMPLETED | PHASE3 |